<DOC>
	<DOCNO>NCT01468558</DOCNO>
	<brief_summary>Compare DHE pharmacokinetic profile observe follow administration : 1 . MAP0004 ( oral inhalation DHE ) 2 . MAP0004 co-administered oral Ketoconazole 3 . Intravenous ( IV ) DHE ( D.H.E.45Â® , approve reference therapy ) Compare tolerability MAP0004 , IV DHE , MAP0004 co-administration Ketoconazole .</brief_summary>
	<brief_title>Pharmacokinetics &amp; Tolerability Study MAP0004 Co-administered With Ketoconazole</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Dihydroergotamine</mesh_term>
	<criteria>Major Able provide write Informed Consent Male Female subject 18 45 year old Female subject practice adequate contraception sterile Stable cardiac status Normal rhythm arrhythmia deem clinically insignificant ECG Contraindication dihydroergotamine mesylate ( DHE ) Use exclude concomitant medication within 10 day prior Visit 1 History hemiplegic basilar migraine Participation another investigational trial 12 week prior Visit 1 trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Drug Drug Interaction Study Normal Healthy Volunteers</keyword>
</DOC>